Evidence map›Paper›PMID 21715287›Full record

ArticleThe Journal of biological chemistry2011

A hypomorphic mutation in Lpin1 induces progressively improving neuropathy and lipodystrophy in the rat.

Joram D Mul, Karim Nadra, Noorjahan B Jagalur, Isaac J Nijman, Pim W Toonen, Jean-Jacques Médard, Sandra Grès, Alain de Bruin, Gil-Soo Han, Jos F Brouwers and 5 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. A review of phosphatidate phosphatase assays.Journal of lipid research · 2020
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 4 countries.

Joram D MulHubrecht Institute-KNAW and University Medical Center Utrecht, 3584 CT Utrecht, The Netherlands.
Karim Nadra
Noorjahan B Jagalur
Isaac J Nijman
Pim W Toonen
Jean-Jacques Médard
Sandra Grès
Alain de Bruin
Gil-Soo Han
Jos F Brouwers
George M Carman
Jean-Sébastien Saulnier-Blache
Dies Meijer
Roman Chrast
Edwin Cuppen
University of Lausanne · CHErasmus MC · NLHubrecht Institute for Developmental Biology and Stem Cell Research · NLRutgers, The State University of New Jersey · USUniversity Medical Center Utrecht · NLUtrecht University · NLInserm · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

Phospholipid metabolism and membrane functionR37GM028140 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI CARMAN, GEORGE M. · 2010 to 2019
$4.0M
PHOSPHOLIPID METABOLSIM AND MEMBRANE FUNCTIONR01GM028140 · NIGMS · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI CARMAN, GEORGE M. · 1985 to 2009
$3.2M
NIGMS NIH HHS GM-28140NIGMS NIH HHS R01 GM028140NIGMS NIH HHS R37 GM028140
6 · The paper itself

Abstract

The Lpin1 gene encodes the phosphatidate phosphatase (PAP1) enzyme Lipin 1, which plays a critical role in lipid metabolism. In this study we describe the identification and characterization of a rat model with a mutated Lpin1 gene (Lpin1(1Hubr)), generated by N-ethyl-N-nitrosourea mutagenesis. Lpin1(1Hubr) rats are characterized by hindlimb paralysis and mild lipodystrophy that are detectable from the second postnatal week. Sequencing of Lpin1 identified a point mutation in the 5'-end splice site of intron 18 resulting in mis-splicing, a reading frameshift, and a premature stop codon. As this mutation does not induce nonsense-mediated decay, it allows the production of a truncated Lipin 1 protein lacking PAP1 activity. Lpin1(1Hubr) rats developed hypomyelination and mild lipodystrophy rather than the pronounced demyelination and adipocyte defects characteristic of Lpin1(fld/fld) mice, which carry a null allele for Lpin1. Furthermore, biochemical, histological, and molecular analyses revealed that these lesions improve in older Lpin1(1Hubr) rats as compared with young Lpin1(1Hubr) rats and Lpin1(fld/fld) mice. We observed activation of compensatory biochemical pathways substituting for missing PAP1 activity that, in combination with a possible non-enzymatic Lipin 1 function residing outside of its PAP1 domain, may contribute to the less severe phenotypes observed in Lpin1(1Hubr) rats as compared with Lpin1(fld/fld) mice. Although we are cautious in making a direct parallel between the presented rodent model and human disease, our data may provide new insight into the pathogenicity of recently identified human LPIN1 mutations.

Indexed as

IntronsMutationAlkylating AgentsAnimalsDemyelinating DiseasesEthylnitrosoureaHEK293 CellsHumansLipodystrophyMiceMutagenesisPancreatitis-Associated ProteinsPhosphatidate PhosphataseProtein Structure, TertiaryRatsRats, Mutant StrainsAlkylating AgentsEthylnitrosoureaPancreatitis-Associated ProteinsPhosphatidate PhosphataseREG3A protein, humanRNA Splice Sites

Identifiers

PMID21715287
PMCPMC3143639
OpenAlexW2080345730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.